Article
Dr. Jack Cush reviews the news and journal reports from RheumNow.com - and the top 5 reasons to attend RheumNow Live 2026, which is one week away.
All News
Article
The The Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group studied giant cell arteritis with aortitis, comparing the efficacy of intravenous vs. subcutaneously (SC) tocilizumab (TCZ) - demonstrating the superiority of SC TCZ.
Article
Retraction of rheumatology studies is not uncommon; a recent analysis shows retractions have risen substantially.
Article
Dr. Cush addresses the management of difficult-to-treat rheumatoid arthritis (D2TRA).
Article
Patients with osteoarthritis (OA) primarily affecting only one knee joint compartment did just as well with partial knee replacement (PKR) as with total arthroplasty after 10 years in a randomized trial -- and maybe a little bit better.
Article
JAMA Dermatology has published the results of a juvenile localized scleroderma (JLS) trial showing that mycophenolate mofetil (MMF) and methotrexate (MTX) are equally effective in treating JLS, noting low flare rates and possibly better tolerability with MMF.
Article
The current issue of Arthritis & Rheumatology reviews current understanding of the immunopathogenesis of Sjögren disease (SjD) and how that has influenced the quest for drug development for this most systemic autoimmune disorder.
Article
A coalition of leading international experts have released the first comprehensive Consensus Statement on the Management of Vertebral Fractures in Chronic Kidney Disease (CKD) Stages G4–G5D.
Article
A 5 year JAMA study shows that a treat-to-target (serum urate < 6 mg/dL) study finds that effective urate-lowering treatment (ULT) results in a significantly reduced cardiovascular risk in patients with gout.
Article
A recent study examines trends in rheumatoid arthritis (RA)-related mortality among U.S. postmenopausal women (aged 55 and older). They found RA mortality rates have declined, yet disparities in who is most affected persist, especially for white women, and those over 85 yrs of age.
Dr. John Cush
Tweet
Full read review of the Mechanistic Effects of Methotrexate in the Treatment of Rheumatoid Arthritis. https://t.co/PrMyZ7q3wX download here: https://t.co/aRnmRm770Z https://t.co/5B0mBjzOXQ
Dr. John Cush
Tweet
Roche Canada announced that Health Canada has approved obinutuzumab (Gazyva) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy. Following four initial doses in the first year, Gazyva can be administered twice yearly https://t.co/P4dCVkoPCH
Dr. John Cush
Tweet
Electronic EHR reminders to deprescribe works! EHR study of 1146 pts(mean 74 yrs) showed 2 methods of E-reminder notifications resulted in either a 10.4% or 6.5% deprescribing (vs usual care); deprescribing was 40% more likely (RR 1.40; 95% CI, 1.14-1.73) https://t.co/sXnW5gUP0q https://t.co/n9LhUG612M
Dr. John Cush
Tweet
Full read review of the Mechanistic Effects of Methotrexate in the Treatment of Rheumatoid Arthritis. https://t.co/PrMyZ7q3wX download here: https://t.co/fvEocwsXIv https://t.co/ZWVctochHV
Dr. John Cush
Tweet
Japanese nationwide survey of 1943 RMD pts taking Azathioprine (AZA) 34% had adverse events: hepatobiliary (149%), GI (10%), blood/lymphatic (9%), infections (5%), & skin (2.4%). AEs lead to 71% D/C AZA. Serious AEs (Gr ≥3) higher w/ older (OR 2.5), & SLE (OR 2.3) https://t.co/lVNYVQATfx
Dr. John Cush
Tweet
Rheum Poll> Which is the most difficult to treat RA (D2TRA) patient (despite aggressive Rx)?
Dr. John Cush
Tweet
Advanced Practice Rheum: Methotrexate
https://t.co/PHAFWBG4gJ https://t.co/p9cMqT4nhR
Dr. John Cush
Tweet
Rheum Poll> Which is the most difficult to treat RA (D2TRA) patient (despite aggressive Rx)?
Dr. John Cush
Tweet
APPIPRA Study - Benefits of Early Treatment
Treating people who are at high risk of rheumatoid arthritis (RA) can delay the onset of the disease for several years, with benefits also continuing well after treatment has stopped.
https://t.co/hgxj936CWn https://t.co/eJX3amp3Id
Dr. John Cush
Tweet
UCAN CAN-DU study of 181 JIA pts starting biologics. Early Rx w/in 6 mos (n=35) assoc. w/ greater odds of achieving inactive arthritis (83% vs 57% in late starters (>12 mos). For each month of delay increased the odds of future active arthritis (after 6 mos) by 9%.
